Andrew Berens, an analyst from Leerink Partners, reiterated the Hold rating on Zentalis Pharmaceuticals (ZNTL – Research Report). The associated price target remains the same with $5.00.
Andrew Berens has given his Hold rating due to a combination of factors surrounding Zentalis Pharmaceuticals’ current position and future prospects. The company recently reported its fourth-quarter and full-year 2024 financial results, with all pipeline programs remaining on track. However, despite the stock being below the fundamental value assessment, it is expected to remain within a certain range due to the broader biotech market conditions and the absence of immediate catalysts to alleviate investor concerns about the therapeutic window of WEE1.
While there are potential future catalysts, such as the DENALI Part 2 trial and the Phase 2 TETON trial in uterine serous carcinoma, these are not expected to provide immediate de-risking opportunities. The management’s cautious optimism about the USC opportunity and its read-out in the first half of 2026 further supports the Hold rating. Additionally, data from the DENALI study presented at the Society of Gynecologic Oncology 2025 Annual Meeting showed consistent results, but these did not significantly alter the outlook. Therefore, the Hold rating reflects a balanced view of the company’s potential and current market challenges.
In another report released on March 27, Morgan Stanley also maintained a Hold rating on the stock with a $8.00 price target.
ZNTL’s price has also changed dramatically for the past six months – from $3.750 to $1.790, which is a -52.27% drop .